Scientists identify a broadly neutralizing antibody against all dominant SARS-CoV-2 variants

Researchers in the United States identified a broadly neutralizing antibody (S728-1157 bnAb) that targets the receptor-binding site (RBS) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).